Vectibix and Peripheral sensory neuropathy - a phase IV clinical study of FDA data

Summary:

Peripheral sensory neuropathy is reported as a side effect among people who take Vectibix (panitumumab), especially for people who are male, 50-59 old, have been taking the drug for 1 - 6 months also take Fluorouracil, and have Colorectal cancer metastatic.

The phase IV clinical study analyzes which people have Peripheral sensory neuropathy when taking Vectibix. It is created by eHealthMe based on reports of 8,935 people who have side effects when taking Vectibix from the FDA, and is updated regularly.

What is Vectibix?

Vectibix has active ingredients of panitumumab. eHealthMe is studying from 8,945 Vectibix users. Check the latest studies of Vectibix.

What is Peripheral sensory neuropathy?

Peripheral sensory neuropathy (damage to one or more of your peripheral nerves) is found to be associated with 569 drugs and 717 conditions by eHealthMe. Check the latest studies of Peripheral sensory neuropathy.

On Aug, 11, 2026

8,935 people reported to have side effects when taking Vectibix.
Among them, 22 people (0.25%) have Peripheral sensory neuropathy.

Could Vectibix cause Peripheral sensory neuropathy?

Among these 22 people:

How long have people been on Vectibix when they have Peripheral sensory neuropathy? *

What is the gender of people who have Peripheral sensory neuropathy when taking Vectibix? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Peripheral sensory neuropathy when taking Vectibix? *

What are other drugs people take besides Vectibix? *

Oxaliplatin: 17 people, 77.27%
Fluorouracil: 17 people, 77.27%
Irinotecan Hydrochloride: 4 people, 18.18%
Mesalamine: 1 person, 4.55%
Levoleucovorin Calcium: 1 person, 4.55%

What are other side effects people have besides Peripheral sensory neuropathy? *

Rashes (redness): 9 people, 40.91%
Weakness: 9 people, 40.91%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 9 people, 40.91%
Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 7 people, 31.82%
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 7 people, 31.82%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 6 people, 27.27%
Thrombocytopenia (decrease of platelets in blood): 6 people, 27.27%
Hypokalemia (low potassium): 6 people, 27.27%
Renal Impairment (severely reduced kidney function): 5 people, 22.73%
Dermatitis Acneiform (dermatoses including acne vulgaris, rosacea, folliculitis, and perioral dermatitis): 5 people, 22.73%

What are the existing conditions these people have? *

Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 14 people, 63.64%
Colon Cancer: 5 people, 22.73%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 4 people, 18.18%
Metastases To Liver (cancer spreads to liver): 2 people, 9.09%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 9.09%
High Blood Pressure: 2 people, 9.09%
Constipation: 2 people, 9.09%
Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it): 1 person, 4.55%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 1 person, 4.55%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Vectibix and have Peripheral sensory neuropathy?

- Check whether Peripheral sensory neuropathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vectibix:

Vectibix (8,945 reports)

Browse all side effects of Vectibix:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Peripheral sensory neuropathy:

Peripheral sensory neuropathy (569 drugs)

Browse all the conditions that are associated with Peripheral sensory neuropathy:

Peripheral sensory neuropathy (717 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on panitumumab (the active ingredients of Vectibix) and Vectibix (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.